Skip to main content

Find Clinical Trials

Clinical trial condition

Mumps

Explore clinical trials studying Mumps. Study availability and eligibility vary by location and protocol.

66 public trials 3 recruiting studies

Refine in advanced search Browse all conditions

Mumps trial results

Completed

Immunogenicity, Safety of Measles-mumps-rubella-varicella Vaccine (MeMuRu-OKA) Compared to Priorix™ Given With Varilrix™

NCT00352898

Conditions: Chickenpox, DNA Virus Infections, Herpesviridae Infections, +19 more
Locations: GSK Investigational Site Edmonton, Alberta, Canada

GSK Investigational Site Vancouver, British Columbia, Canada

GSK Investigational Site Halifax, Nova Scotia, Canada

GSK Investigational Site Enna, Sicily, Italy

View Trial Details

Completed

Immunogenicity and Safety of a Combined Vaccine to Prevent Measles, Mumps, Rubella and Chickenpox Diseases

NCT00127010

Conditions: Chickenpox, DNA Virus Infections, Herpesviridae Infections, +19 more
Locations: GSK Investigational Site Brussels, Belgium

GSK Investigational Site Leuven, Belgium

GSK Investigational Site Bad Saulgau, Baden-Wurttemberg, Germany

GSK Investigational Site Bönnigheim, Baden-Wurttemberg, Germany

View all 48 locations

View Trial Details

Completed

Immunogenicity and Safety of a Combined Vaccine to Prevent Measles, Mumps, Rubella and Chickenpox Diseases

NCT00127023

Conditions: Chickenpox, DNA Virus Infections, Herpesviridae Infections, +19 more
Locations: GSK Investigational Site Bad Saulgau, Baden-Wurttemberg, Germany

GSK Investigational Site Bönnigheim, Baden-Wurttemberg, Germany

GSK Investigational Site Bretten, Baden-Wurttemberg, Germany

GSK Investigational Site Ehingen, Baden-Wurttemberg, Germany

View all 85 locations

View Trial Details

Completed

Immunogenicity and Safety of Combined Vaccine to Prevent Measles, Mumps, Rubella and Chickenpox Diseases

NCT00126997

Conditions: Chickenpox, DNA Virus Infections, Herpesviridae Infections, +19 more
Locations: GSK Investigational Site Espoo, Finland

GSK Investigational Site Lahti, Finland

GSK Investigational Site Oulu, Finland

GSK Investigational Site Pori, Finland

View all 54 locations

View Trial Details

Completed

Assess GSK Biologicals' MMR Vaccine (Priorix) When Given to Healthy Children at the Age of 12 to 18 Months in Singapore.

NCT00388440

Conditions: Infections, Measles, Mononegavirales Infections, +14 more
Locations: Not specified

View Trial Details

Completed

Long-term Follow-up on Immunogenicity & Safety of Measles-Mumps-Rubella-Varicella (MMRV) Combined Vaccine

NCT00406211

Conditions: Chickenpox, DNA Virus Infections, Herpesviridae Infections, +19 more
Locations: GSK Investigational Site Klagenfurt, Austria

GSK Investigational Site Neufeld/Leitha, Austria

GSK Investigational Site Salzburg, Austria

GSK Investigational Site Villach, Austria

View all 41 locations

View Trial Details

Completed

Study of Immunogenicity, Reactogenicity and Safety of the Combined Measles, Mumps and Rubella Vaccine Produced by Bio-Manguinhos/Fiocruz in Children 12-15 Months of Age, Followed by Tetraviral Vaccine in Children 15-18 Months.

NCT01991899

Conditions: Chickenpox, DNA Virus Infections, Herpesviridae Infections, +19 more
Locations: Instituto Evandro Chagas Belém, Pará, Brazil

View Trial Details

Completed

Comparative Study of the Immunogenicity of MMR (Measles, Mumps and Rubella) Single Dose and Multidose Presentations

NCT01777529

Conditions: Infections, Measles, Mononegavirales Infections, +14 more
Locations: CMS Heitor Beltrão Rio de Janeiro, Brazil

View Trial Details

Completed

Study of the Safety of Menactra® Vaccine When Administered With Other Pediatric Vaccines to Healthy Toddlers

NCT00483574

Conditions: Bacterial Infections, Bacterial Infections and Mycoses, Central Nervous System Bacterial Infections, +35 more
Locations: Birmingham, Alabama, United States

Birmingham, Alabama, United States

Dothan, Alabama, United States

Pinson, Alabama, United States

View all 79 locations

View Trial Details

Completed

Immunogenicity and Safety of Pediatric Vaccines When Administered With Menactra® in Healthy Toddlers

NCT00422292

Conditions: Bacterial Infections, Bacterial Infections and Mycoses, Central Nervous System Bacterial Infections, +35 more
Locations: Tuscaloosa, Alabama, United States

Tucson, Arizona, United States

Jonesboro, Arkansas, United States

Little Rock, Arkansas, United States

View all 88 locations

View Trial Details